Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MK 1654

Next Previous
Drug Profile

MK 1654

Alternative Names: Anti RSV F antibody; MK-1654

Latest Information Update: 30 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunostimulants; Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 22 Oct 2019 Phase-II clinical trials in Respiratory syncytial virus infections (Prevention, In adults) in United Kingdom (IV) (NCT04086472)
  • 11 Sep 2019 Merck Sharp & Dohme plans a phase IIa trial for Respiratory syncytial virus infections (Prevention) (IV) in October 2019 (NCT04086472) (EudraCT 2018-003347-28)
  • 03 Oct 2018 Phase-I clinical trials in Respiratory syncytial virus infections (Prevention) in USA (IM, Injection), prior to October 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top